Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer.

Humans Anaplastic Lymphoma Kinase / therapeutic use Carcinoma, Non-Small-Cell Lung / drug therapy Retrospective Studies Lung Neoplasms / drug therapy Protein Kinase Inhibitors / pharmacology ErbB Receptors / therapeutic use Lactams, Macrocyclic / adverse effects

Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
06 2023
Historique:
medline: 14 6 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are highly effective for treatment of

Identifiants

DOI: 10.1200/OP.22.00787 PMID: 37075260
pubmed: 37075260
doi: 10.1200/OP.22.00787
doi:

Substances chimiques

lorlatinib OSP71S83EU
Anaplastic Lymphoma Kinase EC 2.7.10.1
Protein Kinase Inhibitors 0
ErbB Receptors EC 2.7.10.1
Lactams, Macrocyclic 0
EGFR protein, human EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

345-351

Auteurs

Avani M Singh (AM)

Division of Hematology and Oncology at H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL.
ORCID: 0000-0001-7494-2090

Rafael Rubiera-Pebe (R)

Morsani College of Medicine, University of South Florida, Tampa, FL.
ORCID: 0000-0003-3555-9173

Yaser Ahmad (Y)

Morsani College of Medicine, University of South Florida, Tampa, FL.
ORCID: 0000-0002-6474-6325

Michael Shafique (M)

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.

J Kevin Hicks (JK)

Department of Individualized Cancer Management, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
ORCID: 0000-0003-2314-0164

Tawee Tanvetyanon (T)

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
ORCID: 0000-0002-1287-1757

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Kinase du lymphome anaplasique › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Safety Monitoring Activity During EGFR or...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Safety Monitoring Activity During EGFR or...